Cas:28593-13-7 1-Fluoro-3-pentylbenzene manufacturer & supplier

Chemical Name:1-Fluoro-3-pentylbenzene

CAS.NO:28593-13-7

Synonyms:m-Fluorpentylbenzol

Molecular Formula:C₁₁H₁₅F

Molecular Weight:166.23500

HS Code:2903999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:166.11600

LogP:3.55840

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like m-Fluorpentylbenzol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,m-Fluorpentylbenzol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,m-Fluorpentylbenzol Use and application,m-Fluorpentylbenzol technical grade,usp/ep/jp grade.

Related News: The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations. 1-Fluoro-3-pentylbenzene manufacturer He was the partner of a 38-year-old Chinese woman who was travelling with him. She was the first confirmed case reported in the Philippines. 1-Fluoro-3-pentylbenzene supplier Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country. 1-Fluoro-3-pentylbenzene vendor Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country. 1-Fluoro-3-pentylbenzene factory There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association.